Story
The Full Story
Daqo's story changed fundamentally between 2022 and 2025. For a decade, management told a simple, credible story: relentless capacity expansion, relentless cost reduction, growing into the world's cheapest polysilicon. That story was validated spectacularly in 2022 when revenue hit $4.6B and margins reached 74%. Then the industry they helped build overbuilt itself, prices collapsed 85% in two years, and the same capacity that made Daqo a cost leader became the anchor dragging the entire industry underwater. Management's credibility on operational execution remains high — they delivered every expansion phase on schedule. But their credibility on market timing and capital allocation is now in question: they tripled capacity at the cycle peak, and the $100M buyback they announced has been largely unexecuted while the stock fell 77% over five years. The current story is simpler but more fragile: survive on the balance sheet, wait for government-enforced consolidation, and hope that being the last one standing is enough.
The Narrative Arc
The chart tells the story more efficiently than any narrative. Revenue rose 13x from 2019 to 2022, then fell 86% to 2025. Gross margin went from 74% to negative 21% in two years. This is not a company-specific failure — it is a commodity cycle playing out at industrial scale. But Daqo amplified its exposure by tripling capacity (105K MT to 305K MT) precisely as prices peaked.
What Management Emphasized — and Then Stopped Emphasizing
Three pivots stand out:
Capacity expansion vanished. In FY2021-2022, every call opened with expansion milestones — Phase 4B, Phase 5A, the grand Baotou framework (200K MT solar poly, 21K MT semiconductor, 300K MT silicon metal). By FY2025, all future phases were indefinitely shelved. The Shihezi industrial park (RMB 15B investment for 300K MT silicon metal + 100K MT polysilicon) announced in December 2023 has not been mentioned since.
Government policy replaced demand growth. In FY2021-2022, management cited China solar installation records (53 GW, 87 GW, 217 GW, 277 GW) as proof of secular demand. By mid-2025, every earnings call centered on government anti-involution policy: the People's Daily editorial, the draft Price Law amendment, the multi-ministry symposium. By Q1 2026, the CEO explicitly said: "If no policy materializes, company will lower utilization and sell at market pricing."
The balance sheet narrative inverted. In the boom years, the $2B+ liquid asset position was background context. By 2024-2025, it became the central thesis — the reason Daqo would survive while competitors went bankrupt.
Risk Evolution
The risk profile has fundamentally rotated. In FY2021, the dominant risks were geopolitical — the US Entity List designation (June 2021), HFCA Act delisting threat, and Xinjiang forced labor allegations. By FY2025, these risks haven't disappeared but are secondary to the existential market risk: polysilicon prices below cash cost for most of the industry, with 2.2 million MT of nameplate capacity chasing 1.4-1.6 million MT of effective demand.
The new dominant risk is regulatory dependence. Daqo's recovery thesis now hinges on Chinese government willingness to enforce anti-involution policies — production quotas, price floors, capacity retirement. This is a binary risk the company has never faced before.
How They Handled Bad News
Management handled the downturn with a mix of honesty and strategic framing. They were candid about the severity of overcapacity but consistently positioned Daqo as the inevitable winner of the shakeout.
The 2024 impairment ($176M on older lines). Management disclosed it forthrightly — older Xinjiang production lines were impaired because polysilicon prices made them unrecoverable. No attempt to hide it or spread it across quarters. This was credible.
The pricing miss. In Q4 2024, Deputy CEO Anita Zhu guided H1 2025 polysilicon pricing to RMB 40-45/kg. Actual spot prices spent most of H1 2025 in the RMB 35-42/kg range, with significant periods below RMB 37. Management acknowledged this in Q1 2025 but reframed around "longer than previous cycles" rather than admitting the forecast was optimistic.
The buyback non-execution. In Q2 2025, the company announced a $100M buyback. By Q4 2025, management was still describing a "wait-and-see approach." In Q1 2026, Daqo discussed selling Hong Kong-listed shares to fund US ADR buybacks — suggesting the original buyback had barely been executed. Management never quantified how much of the $100M was actually spent during the downturn.
Guidance Track Record
Credibility Score (1-10)
Management earns a 5/10. Their operational execution is genuinely best-in-class — every expansion phase delivered within months of schedule, production cost fell from $14/kg to $4.46/kg over a decade. But their market calls have been consistently optimistic (pricing guidance missed in both directions, always upward), and the $100M buyback announcement during a downturn — when the stock was cheap and the balance sheet had $2.2B in liquid assets — followed by non-execution is the single largest credibility gap in the story.
What the Story Is Now
The current story is: Daqo is a well-run, low-cost polysilicon producer with a fortress balance sheet ($2B+ liquid assets, zero debt), waiting for an industry shakeout that will reward survivors with pricing power. The company is operating at 30-57% utilization, refusing to sell below cost, and betting that government-enforced anti-involution policies will drive high-cost competitors out of the market.
What has been de-risked:
Survival. With $2B in liquid assets and zero debt, Daqo can sustain losses for years. Cash burn was approximately $80M/quarter in Q4 2024, but improved to positive operating cash flow by Q3-Q4 2025. The HFCA Act delisting risk was substantially reduced when the PCAOB completed its inspection of mainland China auditors in December 2022.
What still looks stretched:
The government intervention thesis. Management is now explicitly dependent on Chinese regulators enforcing price floors and production quotas. The People's Daily editorial, the draft Price Law amendment, the multi-ministry symposiums — these are signals, not enforcement. In Q1 2026, the CEO admitted that if policy doesn't materialize, the company simply cuts utilization and sells at market. The post-consolidation price target of RMB 60-80/kg remains aspirational.
The expansion capital allocation. Between Phase 5A, 5B, and related projects, Daqo invested approximately $2.5B in capacity additions that came online into the worst polysilicon market in the company's history. The Shihezi industrial park (RMB 15B planned investment) has gone quiet. The 1,000 MT semiconductor polysilicon project began trial production but has generated no visible revenue.
What the reader should believe: That Daqo will survive the downturn — the balance sheet makes this near-certain. What the reader should discount: That survival alone will restore returns. The path from here to profitability runs through either government-mandated capacity retirement (binary, unpredictable) or a multi-year organic attrition of weaker players (slow, painful). The stock trades at 0.3x book value, pricing in deep skepticism. Whether that skepticism is warranted depends on a single question: will Beijing enforce the anti-involution policies it has signaled? Daqo has no control over the answer.
The story has shifted from one of operational control — build capacity, cut costs, grow volumes — to one of external dependence: government policy, competitor bankruptcy, pricing recovery. This is a fundamentally different investment thesis than the one that drove the stock from $9.50 at IPO to peak levels above $90.